|Dr. Bruce L. Booth Ph.D., D.Phil.||Co-Founder & Chairman||26.53k||N/A||1974|
|Dr. Nello Mainolfi M.D., Ph.D.||Co-Founder, Pres, CEO & Director||832.62k||N/A||1979|
|Dr. Richard Chesworth Ph.D.||Chief Scientific Officer||447.88k||N/A||1970|
|Dr. Jared A. Gollob||Chief Medical Officer||577.21k||N/A||1964|
|Mr. Bruce N. Jacobs CFA||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Brian Albarran M.B.A., Ph.D.||VP of Strategy & Operations||N/A||N/A||N/A|
|Mr. Michael J. Todisco||VP of Accounting & Fin.||N/A||N/A||1965|
|Mr. Paul Cox||VP of Investor Relations & Communications||N/A||N/A||N/A|
|Ms. Karen Martin J.D., Ph.D.||VP & Head of Legal||N/A||N/A||N/A|
|Ms. Paige Cochran||VP of HR||N/A||N/A||N/A|
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 8.